Charles Schwab Investment Management Inc Otonomy, Inc. Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $52,200 - $97,050	-15,000 Reduced 47.11%	16,843 $109,000
Q3 2020 Nov 13, 2020	BUY	$3.16 - $4.36 $100,623 - $138,835	31,843 New	31,843 $129,000
Q3 2019 Nov 08, 2019	SELL	$2.12 - $2.86 $37,494 - $50,581	-17,686 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$1.8 - $2.97 $31,834 - $52,527	17,686 New	17,686 $47,000
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.95 $212,550 - $322,912	-81,750 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$3.7 - $4.75 $121,604 - $156,113	-32,866 Reduced 28.67%	81,750 $315,000
Q1 2018 May 07, 2018	BUY	$4.05 - $6.1 $15,163 - $22,838	3,744 Added 3.38%	114,616 $482,000
Q4 2017 Jan 17, 2018	BUY	$2.8 - $5.55 $310,441 - $615,339	110,872	110,872 $616,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.